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Apoptosis plays a role in pemphigus IgG-dependent acantholysis; theoretically, the blockade of the caspase pathway could prevent
the blistering that is caused by pemphigus autoantibodies. Using this strategy, we attempted to block the pathogenic eﬀect of
pemphigus IgG in Balb/c mice by using the caspase inhibitor Ac-DEVD-CMK. This inhibitor was administrated before the
injection of pemphigus IgG into neonatal mice. The main results of the present investigation are as follows: (1) pemphigus
IgG induces intraepidermal blisters in Balb/c neonatal mice; (2) keratinocytes around the blister and acantholytic cells undergo
apoptosis; (3) the caspases inhibitor Ac-DEVD-CMK prevents apoptosis; (4) the inhibition of the caspase pathway prevents blister
formation. In conclusion, inhibition of the caspase pathway may be a promising therapeutic tool that can help in the treatment of
pemphigus ﬂare ups.
1.Introduction
Pemphigus is an autoimmune disease characterised by the
development of intraepidermal blisters. These lesions are
associated with the deposition of antidesmoglein autoanti-
bodiesalongdesmosomestructures;suchdepositionsinduce
cell detachment or acantholysis. Pemphigus IgG targets
include desmosomal proteins [1].
The pathogenesis of pemphigus has been better eluci-
dated than other organ-speciﬁc autoimmune diseases. In
addition to its clinical importance, such knowledge has also
contributed to major advances in desmoglein biology and
pathology. Historically, Beutner and Jordon ﬁrst described
the pemphigus antibodies [2], and a signiﬁcant advance in
the understanding of pemphigus pathogenesis was accom-
plished by Anhalt and Diaz, who reproduced the disease
by injecting human pemphigus IgG into Balb/c neonatal
mice. Thus, they developed the ﬁrst experimental model of
pemphigus [3]. Subsequently, Stanley and Amagai proposed
the key concept that autoantibodies against desmogleins are
both essential and suﬃcient for epidermal blister formation
(acantholysis), with autoantibody binding impeding the
normal functioning of these major adhesion proteins [4].
The family of pemphigus autoantibodies is pathogenic
because the passive transfer of pemphigus IgG or the
transfer of splenocytes from recombinant Dsg3-immunised
Dsg3(−/−) mice into experimental animals induces blis-
tering and acantholysis [3–5]. In a similar fashion, human
maternal pemphigus autoantibodies transferred into the
foetus through placental circulation induces neonatal pem-
phigus [6]. Pemphigus autoantibodies speciﬁcally induce
blisterformation,andanti-idiotypeantibodiescanneutralise
theblisteringinducedbytheinjectionofpemphigusIgGinto
Balb/c neonatal mice [7].
Diﬀerentmechanismsofblisterinductionhavebeenpro-
posed; some of them are dependent on pemphigus autoanti-
bodies, which trigger the dissociation of desmoglein bonds,
thus leading to apoptosis [8]. The desmosome dissociation
depends on a rapid and dose-dependent phosphorylation of
p38 mitogen-activated protein kinase (p38MAPK) and heat
shock protein 27 (HSP27). Hyperphosphorylation can be
abrogated by p38MAPK inhibition, which prevents disease2 Autoimmune Diseases
in pemphigus vulgaris mice [9]. However, the biphasic
activation of p38MAPK suggests that apoptosis is a down-
stream event in pemphigus acantholysis. The earlier peak
of p38MAPK activation is part of the mechanism leading
to acantholysis, whereas the later peak of p38MAPK and
apoptosis may not be essential for acantholysis [9].
Regarding to the possible role of apoptosis, there is
an alternative explanation of acantholysis in which the
cells shrink and separate without aﬀecting the desmosomal
bonds at early stages. This explanation is supported by the
observationthatacantholysisinearlypemphigusskinlesions
andkeratinocyteculturesinvitromayoccurintheabsenceof
apoptosis. Additionally, secondary antibody cross-reactivity
with pemphigus autoantibodies bound to the keratinocyte
cell surface may result in signals which induce acantholysis
[10, 11].
One experimental therapeutic approach to treat pemphi-
gus has focused on the prevention of cell detachment by cas-
pase inhibition [9]. This strategy is reasonable because some
studies have suggested that the ﬁnal phase of acantholysis in
pemphigus is Fas mediated [10]. Therefore, pharmacological
approaches based on modifying the apoptotic pathway have
been assessed in vitro for their ability to control blistering
in pemphigus [12, 13]. Here, we study the in vivo role
of apoptosis in blister formation, and we propose that
inhibition of the caspase pathway is a possible therapeutic
approach in experimental pemphigus.
2. Methods
2.1. Patient Sera. Serum that was positive for antiepithelial
antibodies taken from a patient with pemphigus vulgaris
(MCA) was used for IgG puriﬁcation. Clinically, the patient
had active and extensive disease with oral involvement,
a positive Nikolsky’s sign and a skin biopsy that showed
a suprabasal epidermal blister. MCA had a high titre of
antiepithelial antibodies and antidesmoglein 3 antibodies, as
determined using an enzyme-linked immunosorbent assay
(ELISA) (described later).
The control serum was obtained from a healthy indi-
vidual matched by age and sex with the pemphigus patient
(MCA). This serum was used to purify normal IgG as
described later.
2.2. Antiepithelial Antibodies. Antiepithelial autoantibodies
were detected using an indirect immunoﬂuorescence assay
using cow nose as the antigen source and ﬂuorescein
isothiocyanate (FITC)-labelled goat antihuman IgG (Sigma,
St. Louis, MO, USA). The serum was progressively diluted in
PBS (starting at 1:80) and incubated for 30 minutes on 4μm
sections of cow nose. After washing three times with PBS, the
slides were incubated for 30 minutes with monospeciﬁc goat
antihuman IgG, IgA, or IgM. After washing, the slides were
evaluated under a ﬂuorescent microscope [14].
2.3. Determination of Antidesmoglein Antibodies Using an
ELISA. The ELISA was performed using polystyrene mi-
crowell plates coated overnight at 4◦C with diluted recom-
binant Dsg1 and Dsg3 (175 ng of Dsg/mL in TBS-Ca++,
pH 7.4) (RhiGene, Inc. Woburn, USA). The active sites
of the coated plates were blocked for 1h with 1% bovine
serum albumin dissolved in TBS-Ca++ with 0.05% Tween
20 at pH 7.2. After washing with TBS-Ca++ with 0.05%
Tween 20, 100μL of diluted serum (1:100) was applied
into the coated microwell plates and incubated for 60 min
at room temperature. After ﬁve washes, the plates were
incubated with 100μL of horseradish peroxidase-conjugated
rabbit antihuman IgG (Fab) (Sigma). After a ﬁnal wash
step, the colour reaction was developed through incubation
withTMB substratesolution (3,3 ,5,5 -tetramethylbenzidine
dihydrochloride/hydrogen peroxide; Fluka, Seelze, Ger-
many),for30minutes.Thereactionwasstoppedwith100μL
of 1N sulphuric acid. The optical density was measured at
490nm [15].
2.4. Isolation of Pemphigus IgG. The gamma globulin frac-
tion was precipitated with ammonium sulphate, and the
precipitates were submitted to extensive dialysis against
distilled water using Slide-A-Lyzer Dialysis Cassettes (10K
MWCO Thermo Fisher Scientiﬁc Inc., Rockford, IL). IgG
was puriﬁed using aﬃnity chromatography using a HiTrap
protein G HP column (polypropylene 1.6 × 2.5cm column
packed with 5mL of recombinant protein G Sepharose).
The column was equilibrated with binding buﬀer (20mM
sodium phosphate), and IgG was eluted in ﬁve volumes
of elution buﬀer (0.1M glycine-HCl, pH 2.7). The elution
fractions were neutralised with Tris-HCl (pH 9.0), and the
protein content was detected using a spectrophotometer at
280nm (Beckman Coulter DU 640). Pure IgG was char-
acterised on 10% polyacrylamide-sodium dodecylsulphate
(SDS) gels [16].
2.5. Passive Transfer into Balb/c Mice. The IgG fractions
from pemphigus vulgaris and normal sera puriﬁed using
aﬃnity chromatography were concentrated to 100mg/mL
and ﬁlter sterilised. A dose of 1mg IgG per gram of body
weight was intraperitoneally administered to Balb/c neonatal
mice, as previously reported [3] .T h ea n i m a l sw e r ee v a l u a t e d
clinically and histologically and using immunoﬂuorescence
24h after injection. The experimental groups included nine
animals per group, which were divided as follows: (a) a
controlgroupinjectedwithPBS;(b)anegativecontrolgroup
injectedwithnormalIgG,obtainedfromhealthyindividuals;
(c) a positive control group injected with pemphigus IgG;
(d) an experimental group injected intraperitoneally with
Ac-DEVD-CMK (Calbiochem Cat. no. 218750) 2h before
injection with pemphigus IgG. The caspase inhibitor Ac-
DEVD-CMKwasdissolvedinDMSOandadjustedto20mM
in PBS to a ﬁnal volume of 50μL. Serum samples and
biopsies were collected immediately after the animals were
sacriﬁced. All 36 test animals were injected simultaneously.
All experiments were conducted according to the guide-
lines for ethical conduct in the care and use of animals
developed by the American Psychological Association (APA)
(http://www.apa.org/science/anguide.html).
2.6. Tissues. Skin punch biopsies (3mm) were performed
on the experimental animals. One biopsy was processedAutoimmune Diseases 3
using direct immunoﬂuorescence and another biopsy was
embedded in paraﬃn and processed immunohistochemical
stainingandhaematoxylinandeosin(H&E)stainingorTdT-
mediated dUTP nick end labelling (TUNEL) and annexin V
staining.
2.7. Direct Immunoﬂuorescence. A4 μm slice of skin was
obtained using cryosectioning. The tissues were rinsed in
0.15M PBS, and any possible immune depositions were
detected after incubation with FITC-conjugated rabbit anti-
human IgG, IgM, IgA, C1Q, C3, or C4 (Sigma). After a
30-minute incubation, the slides were rinsed, mounted in
glycerol-PBS and evaluated using ﬂuorescent microscopy
(described later).
2.8. Detection of Apoptotic Features. Programmed cell death
was determined using two methods. First, the presence of
phosphatidylserine on the outer leaﬂet of apoptotic mem-
branes was detected using an Annexin-V-FLUOS Staining
kit (Roche Diagnostics GmbH). Second, the presence of
apoptotic DNA breaks was assessed using TUNEL stain-
ing according to the manufacturer’s instructions (Roche
Molecular Biochemicals, Penzberg, Germany). Positive and
negative controls were included for each technique. To
diﬀerentiate the true green tag of apoptotic cells from
background ﬂuorescence, tissues were counterstained with
0.5% propidium iodide, which stains nonapoptotic nuclei
red. The slides were washed in PBS and evaluated using a
confocal scanning microscope (LSM Axiovert 200M, Carl
Zeiss, G¨ ottingen, Germany). Combinations of ﬂuorescein
ﬁlters with excitations of 450–490nm and rhodamine ﬁlters
with emissions of 515–565nm were used; the objectives were
LCI “Plan-Neoﬂuar,” and images were processed using a
Zeiss LSM Image examiner.
2.9. Immunohistochemistry. Caspase 3, Fas and FasL were
detected using immunohistochemistry in paraﬃn-embed-
ded 4μm thick sections of murine skin, whichwere dewaxed.
Brieﬂy, slides were permeabilised with 0.01% Triton X-
100/PBS and washed three times with PBS. Endogenous
peroxidase was blocked with horse serum that was heat
inactivated at 56◦C. After washing, tissues were incubated
separatelyfor12hwiththefollowingmonoclonalantibodies:
anticaspase 3 at a 1:20 dilution (35–1600, Zymed, South
San Francisco, CA), anti-FasR at a 1:50 dilution (35–1600,
Zymed), and anti-FasL at a 1:200 dilution (Sc-1968, Santa
Cruz, CA). Dilutions were made in 10% BFS-PBS. After
washing with PBS, bound antibodies were tagged with goat
antimouse IgG labelled with peroxidase and diluted 1:100
(62–6620, Zymed). The colour reaction was induced by
2,2 diaminobenzydine in 0.06% H2O2 (Sigma, San Louis,
MO), and the reaction was stopped with 2N sulphuric acid.
Finally, the slides were evaluated using a light microscope.
The assays were performed in triplicate, and the results were
evaluated by two observers in a blind fashion.
2.10. Caspase Activity. Caspase 3 activity was evaluated in
skin extracts. Brieﬂy, tissues were washed with cold PBS,
pH 7.2, and disrupted in 200μLo fl y s i sb u ﬀer (1% Triton
X-100, 140mM NaCl, 1mM EDTA, 10mM Tris-HCI, pH
7.6, and 1mM PMSF). Tissue extracts were homogenised
and centrifuged at 14,000 rpm for 10 minutes at 4◦C.
The supernatants containing soluble fractions were run on
10% SDS-PAGE gels [16], which were then transferred
ontonitrocellulosesheets(Hybond-C,Amersham,UK)[17].
Immunoreactive bands were identiﬁed using a 1:1000 dilu-
tion of a monoclonal anticaspase 3 antibody. A peroxidase-
conjugated goat IgG antimouse IgG (Sigma) was used as
the secondary antibody. After a 1h incubation, immunore-
active bands were detected using chemiluminescence (ECL,
RPN2106; Amersham).
Caspase 3 activity was also detected through staining
of the cytoskeletal protein cytokeratin 18 (CK18), using
the M30 CytoDeath antibody, which binds to a caspase-
cleaved, formalin-resistant form of CK18 (Roche Applied
Science, Mannheim, Germany). Paraﬃn-embedded tissue
sections were dewaxed, and antigen retrieval was performed
by heating in citric acid buﬀer (2g/l citric acid, pH 6,
adjusted with 1N NaOH). Then, tissues were blocked with
PBS containing 1% BSA and 0.1% Tween 20, followed by
incubation with the M30 antibody for 1h at 15 to 25◦Ci n
a humidiﬁed chamber. Tissues were then washed two times
with PBS, followed by a 30-minute incubation at 37◦Ci n
a humidiﬁed chamber with a biotinylated antimouse-IgG
antibody.AfterwashingtheslideswithPBS,thesectionswere
incubated with 0.5U/mL streptavidin-POD (Roche Applied
Science, Mannheim, Germany) for 30min at 15 to 25◦Ci na
humidiﬁed chamber, and the colour reaction was developed
byincubationinafreshlypreparedsubstratesolutionofDAB
substrate (Roche Applied Science, Mannheim, Germany) at
15 to 25◦C until a clearly visible colour developed. The reac-
tion was stopped using extensive rinsing in double-distilled
water. Slides were counterstained with Harris haematoxylin,
mountedinKaiser’sglycerolgelatin,andobservedusinglight
microscopy.
2.11. Statistical Analyses. Data were processed using a Chi-
squared test with Yate’s correction using the GraphPad
Software, QuickCalcs; P<. 005 was considered statistically
signiﬁcant.
3. Results
3.1. Pemphigus Serum Characterisation. The serum from a
34-year-old female patient who had pemphigus vulgaris for
two years was used for IgG isolation. This serum sample
was collected during a pemphigus ﬂareup in which the
patient exhibited extensive blistering aﬀecting 70% of the
skin surface in addition to the mouth and mucous epithelia.
This patient tested positive for antiepithelial antibodies at a
1:2560 reciprocal titre for the IgG class; autoantibodies of
the IgA and IgM class were negative, and she tested positive
for antidesmoglein 1 at a concentration of 17.3U/mL
(normal value = 3.6) using ELISA. She also displayed
antidesmoglein 3 autoantibodies at a concentration of
106U/mL (normal value = 7).4 Autoimmune Diseases
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Figure 1: (a) Patient with pemphigus vulgaris showing extensive blistering in trunk and mouth. (b) Skin biopsy stained with H&E
showing intraepidermal blister (double arrow) and acantholytic cells (arrow). (c) Patient sera showed antiepithelial antibodies using
indirect immunoﬂuorescence. (d) Intraepidermal blister showing that apoptotic cells (green) detected using TUNEL and counterstained
with propidium iodide were present in the lesional area (square). (e) Isolation of pemphigus IgG using aﬃnity chromatography. The
chromatogram shows that the IgG peak was in fractions 7–9. OD: optical density. The bottom panel shows an SDS-PAGE gel of the eluted
fractions.
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Figure 2: Induction of acantholysis in Balb/c mice and the prevention of blistering by caspase inhibition. The top panel shows representative
ﬁgures of a negative control Balb/c mouse injected with normal IgG. This mouse did not develop blisters, show IgG deposition along
intercellular spaces or initiate apoptosis. The middle panel shows a mouse injected with pemphigus vulgaris IgG that developed macroscopic
abdominal and leg blisters. H&E staining shows that blisters were suprabasally located (arrow) with acantholytic cells (arrow), also PV-IgG
was deposited in the roof and base (arrow) of the blister, and apoptotic cells are shown in green (arrow) as demonstrated using TUNEL
and annexin staining. The bottom panel shows a mouse treated with the Ac-DEVD-CMK peptide prior to pemphigus IgG injection.
The skin biopsy was taken 24h after injection. The animal did not develop blisters despite the PV-IgG deposition along intercellular
spaces. The caspase inhibitor blocked apoptosis of keratinocytes (red). PV-IgG: pemphigus vulgaris IgG. H&E: haematoxilin and eosin.
IF: immunoﬂuorescence.Autoimmune Diseases 5
3.2. Histology. The skin biopsy stained using H&E showed
a suprabasal intraepidermal blister with acantholytic cells
(Figure 1). Using a direct immunoﬂuorescence assay, exten-
sive IgG deposition was visualised along the intercellular
spaces of lesional and perilesional areas. Furthermore, we
hypothesised that the pemphigus IgGs induce apoptosis
because extensive apoptotic features were present in the
patient’s biopsy, as demonstrated using TUNEL and annexin
staining techniques; no apoptotic features were observed in
nonlesional skin of the patient. In contrast, apoptosis was
observed in aﬀected skin. The apoptotic cells found in the
blister roof diﬀered from apoptotic cells found following
terminal skin diﬀerentiation (Figure 1).
3.3. IgG Puriﬁcation. IgG puriﬁed using aﬃnity chromatog-
raphy yielded a peak in fractions 7–9, as shown using SDS-
PAGE. These fractions were used to inject experimental
animals. Antiepithelial IgG was positive, with a 1:2560
reciprocal titre exclusive of the IgG class, and antidesmoglein
activity was also positive (Figure 1). Puriﬁed IgG fractions
were used to induce pemphigus lesions.
3.4. Pemphigus IgG Triggers Acantholysis in Balb/c Mice. The
group of animals that was injected with pemphigus IgG
developed positive Nikolsky’s signs, and seven of the nine
mice developed blisters 24 hours after injection. Accordingly,
the sera samples from these mice had positive antiepithelial
antibodies, which were of human origin. Using histology,
skin biopsies exhibited suprabasal intraepidermal blistering
with multiple acantholytic cells, and immunoﬂuorescence
analysis showed IgG deposition along the intercellular spaces
of involved and noninvolved skin. Apoptotic features were
broadly distributed in lesional areas, mimicking the ﬁndings
of the patient biopsy. Positive and negative controls of
apoptosis were included. For the positive control, biopsies
were digested with nucleases prior to staining and showed
positive ﬂuorescence along the epidermal and dermal nuclei.
The negative control biopsies were processed without the
TdT enzyme and thus showed no nuclear ﬂuorescence
(Figure 2).
3.5. Pemphigus IgG Induces Caspase 3 Activation. To assess
whether pemphigus IgG activated caspase 3, skin extracts
were characterised using SDS-PAGE, and caspase 3 was
probed with an anticaspase 3 monoclonal antibody. The
results showed that normal IgG did not activate caspase
3. In the control group, a protein of 32kDa was detected,
which corresponds to zymogen. In contrast, in the skin
extracts of animals injected with pemphigus IgG, two bands
were detected: one at 32kDa, which corresponds to the
proenzyme, and the other at 16kDa, which corresponds to
the active caspase 3 fragment (Figure 3).
Another assay to evaluate caspase activity utilises the
antibody M30, which recognises a neoepitope of cytokeratin
18 formed after caspase cleavage. This antibody does not
bind the native or unmodiﬁed CK18 of normal cells.
TissuesexpressingCK18apoptoseuponactivationofeﬀector
caspases 3, 6, 7, or 9. Animals injected with pemphigus IgG
were tagged with the antibody M30, and they were found to
express this surrogate marker in blister and perilesional areas
but not in uninvolved skin. This tag was absent in the skin of
the control group (Figure 4).
3.6. Caspases Inhibition Prevents Blistering. Our results
demonstrated that PV-IgG induced blistering, and immuno-
histochemistryresultsshowedabroaddistributionofcaspase
3 and Fas/FasL pairs in the blisters of animals treated with
PV-IgG. These proteins were faintly detectable in controls.
In addition, because the blisters were stained using the
antibody M30, we deduce that PV-IgG induces caspase
cascade activation that leads to apoptosis. Additionally, the
16kDa active caspase 3 fragments detected in the skin of
animals injected with PV-IgG demonstrated that caspase
cascades were involved in blistering (Table 1).
Based on previous results, we investigated whether
blocking caspases could prevent blistering. The group of
animals treated with Ac-DEVD-CMK for 2 hours before
injection with pemphigus IgG did not show blisters or
Nikolsky’s signs 24 hours after IgG administration although
they had antiepithelial antibodies. The skin of these animals
did not exhibit apoptotic features (Figure 2). They exhibited
faint deposition of caspase 3 and Fas, but the caspases were
not activated (Figure 3). No side eﬀects of the Ac-DEVD-
CMK injections were clinically detected in the mice in vivo
or during necropsy.
Based on these results, we postulate that the pemphigus
antibody induces disassembly of the desmosome, which in
turn induces a downstream signal transduction cascade that
leads to apoptosis. Control groups injected with PBS or
normal IgG did not develop blisters, IgG deposition, or
apoptosis (Figure 2 and Table 1).
4. Discussion
In the present work, we explored an alternative treatment
approach for experimental pemphigus based on modifying
caspase-related events.
The current investigation shows the following: (1) pem-
phigus IgG induces acantholysis in Balb/c neonatal mice,
(2) pemphigus IgG-dependent acantholytic cells undergo
apoptosis, and (3) caspase inhibition prevents apoptosis and
acantholysis in vivo.
Previous observations have demonstrated that the blis-
tering process in pemphigus is antibody dependent, and
that blisters are caused by a mechanism that involves the
binding of pemphigus IgG to the extracellular domains of
desmogleins. This binding induces a downstream kinase sig-
nal transduction cascade that leads to desmoglein dissocia-
tion from the plakoglobin plate and desmosomal breakdown
[18]. Simultaneously, a Fas-mediated downstream signal
transduction cascade is triggered and leads to the apoptosis
of acantholytic cells [19–21].
Caspases are cysteine proteases that are activated in
cascades during programmed cell death. Caspase 3 is the
most important caspase because it is involved in both the
intrinsic and the extrinsic pathways of apoptosis. The use6 Autoimmune Diseases
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Figure 3: Mouse skin extracts were analysed using western blot and probed with a monoclonal anticaspase 3 antibody. The ﬁrst line is a
negativecontrolincubatedwithoutantibody.ThesecondlinecorrespondstoaskinextractfromamouseinjectedwithnormalIgG.Notethat
a faint band appears at 32kDa which corresponds to caspase 3 zymogen. The third line corresponds to an animal injected with pemphigus
vulgaris IgG and shows a large band of pro-caspase 3 and an additional band at 16kDa, which corresponds to active caspase 3. The skin
extract from the mouse treated with Ac-DEVD-CMK and injected with pemphigus IgG exhibited only the proenzyme.
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Figure 4: Caspase 3 activity detected in mouse skin. Note the presence of caspase 3 in a blister induced by the injection of pemphigus
vulgaris IgG, and the presence of cytokeratin 18 detected using the antibody M30 which recognises a neoepitope of cytokeratin 18 formed
after caspase cleavage. Positive immunohistochemistry was exhibited in both cases (arrows). Note the inhibition induced by the synthetic
peptide Ac-DEVD-CMK in the bottom row.
of caspase inhibitors to block apoptosis is based on the
notionthatthecatalyticactivesiteofcaspasescontainshighly
conserved motifs with characteristic sequences. This permits
the interaction of complementary peptides that are designed
toregulatetheenzyme’sactivity.Caspase3showsastructural
speciﬁcity for substrates in the S4 pocket, and this motif
requires at least four amino acids to the left of the cleavage
site[22,23].Reversibleandirreversibleinhibitorsofcaspases
have been developed by coupling caspase-speciﬁc peptides
to certain aldehyde, nitrite, or ketone compounds. These
inhibitors can successfully block apoptosis. For instance,
DEVD, which was used in the present work, is a peptideAutoimmune Diseases 7
Table 1: Pemphigus IgG triggers acantholysis in Balb/c mice.
Group (n = 9) (A) Control (B) PV-IgG (C) Ac-DEVD-CMK+PV-IgG P value
Macroscopic blisters 0/9 7/9 0/9 Av e r s u sB< .0037
Bv e r s u sC< .0037
Histology Normal Blisters, acantholysis 7/9 No blisters Av e r s u sB< .0037
Bv e r s u sC< .0037
Direct immunoﬂuorescence Negative IgG on intercellular spaces 9/9 IgG on intercellular spaces 9/9 Av e r s u sB< .0002
Bv e r s u sC> .37
TUNEL Negative Positive 9/9 Negative Av e r s u sB< .0002
Bv e r s u sC< .0002
Annexin Negative Positive 9/9 Negative Av e r s u sB< .0002
Bv e r s u sC< .0002
Caspase 3 0/9 9/9 0/9 Av e r s u sB< .0002
Bv e r s u sC< .0002
Fas 9/9 faint 9/9 strong 9/9 faint Av e r s u sB>.3
Bv e r s u sC>.32
FasL 1/9 9/9 2/9 faint Av e r s u sB< .0009
Bv e r s u sC< .0017
PV: pemphigus vulgaris, (statistically signiﬁcant < 0.05), Chi-squared with Yates’ correction.
that preferentially binds caspase 3, but it can also aﬀect other
caspases such as caspase 6, 7, 8, and 10 [24].
Ourresultsdemonstratethattheacantholysisofpemphi-
gus is linked to apoptosis; therefore, cell death is triggered
by the Fas pathway. Our ﬁnding that apoptotic cells of the
blister roof are diﬀerent from apoptotic features observed
in terminally diﬀerentiated skin of the stratum corneum
strongly suggests that apoptosis in perilesional areas is
caused by acantholysis and represents a pathophysiological
mechanism in pemphigus [11, 25].
Thepresentworkconﬁrmsthatthepan-caspaseinhibitor
Ac-DEVD-CMK prevents the blistering induced by human
pemphigus IgG in living animals and extends the results
obtained by other authors in cultured keratinocytes or
cell lines [11]. These results are of potential therapeutic
interest. Furthermore, the present results show macroscopic
and histological evidence that Ac-DEVD-CMK prevents the
development of both blisters and the initiation of apoptosis,
despite these mice containing circulating human pemphigus
antibodies. This suggests that apoptosis contributes to the
pemphigus antibody role in desmosomal breakdown by
a mechanism that needs to be further elucidated. It is
possible that the cleaving eﬀect of caspases could amplify the
initial damage signal caused by pemphigus autoantibodies.
However, we are certain that the unique conditions found
in pemphigus that triggers apoptosis require the pemphigus
autoantibodies because the injection of normal IgG did not
trigger apoptosis or acantholysis. Our results were conﬁrmed
in additional experiments. The injection of neonatal Balb/c
mice with PV-IgG isolated from diﬀerent PV patients
induced blisters and acantholysis in a similar manner to the
IgG of the MCA patient, and this blistering was blocked in
experimental animals by the caspase inhibitor.
To ensure that the previous results demonstrating acan-
tholysis prevention by Ac-DEVD-CMK were real and not
an epiphenomenon, we biopsied six diﬀerent skin sites
without clinically apparent blisters from the same animals
for histological immunoﬂuorescence and TUNEL analysis.
These samples were representative of an extensive skin area
of each animal. The biopsy analyses showed similar results
to our previous experiments. These mice did not develop
acantholysis, as demonstrated microscopically.
Another consideration is that inhibition of acantholysis
and apoptosis occurred despite the expression of Fas and
faint staining for FasR. These ﬁndings suggest that the pem-
phigus antibodies cause keratinocyte death and dissociation
not only through the extrinsic, but also through the intrinsic
pathway.
TheAc-DEVD-CMKpeptidehaspreviouslybeenusedin
lupus experimental models to prevent apoptosis and tissue
damage by antibody deposition [26, 27]. Here, we extend
these previous observations to pemphigus and conﬁrm the
hypothesis that caspases inhibition can prevent blistering in
pemphigus [10, 12, 13]. This experimental therapy may be a
promising approach to control pemphigus ﬂareups.
Other studies using caspase inhibitors, which were
eﬀective in blocking acantholysis, indicate that the apop-
totic machinery contributes to cell dissociation. However,
Waschke and Rubenstein [28–30] demonstrated that acan-
tholysis might occur in the absence of apoptosis, which
suggests that acantholysis in pemphigus can be dependent or
independent of apoptosis. It has recently been demonstrated
that the structural damage (acantholysis) and death (apop-
tosis) of keratinocytes are mediated by the same cell death
enzymes; thus, the therm of apoptolysis was coined. Apop-
tolysiscausesbasalcellshrinkageandsuprabasalacantholysis
and may have several implications in pathogenic terms
[31]. In the present study, our experimental data indicate
that pemphigus IgG causes acantholysis and desmosome
disassembly in association with caspase 3 activation. Such8 Autoimmune Diseases
a phenomenon can be prevented by a synthetic peptide that
inhibits caspase 3.
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